Alphatec Holdings (ATEC) Company Report

Alphatec Spine reported $764 million in revenue for 2025, a 25% increase, and projects $890 million in revenue for 2026, representing 17% growth.
The company achieved $91 million in Adjusted EBITDA (12% of revenue) in 2025 and forecasts $130 million (15% margin) in 2026, with positive free cash flow in 2025 and $20 million in 2026.
Strategic initiatives include strengthening its position as the third largest U.S. market share holder through proceduralization and informatics, with the Valence navigation and robotic tool expected to launch in 2026.
Alphatec Spine remains committed to its 2027 long-range plan targets of $1 billion in revenue and $180 million in Adjusted EBITDA.

6 days ago

Transcript

Alphatec Spine Reports Strong 2025 Performance and Provides 2026 Guidance

ATEC

Guidance Update

Revenue Acceleration/Inflection

Product Launch

Alphatec Spine (ATEC) finished 2025 with $764 million in revenue, representing 25% growth, and achieved $91 million in Adjusted EBITDA, reaching free cash flow profitability.
The company became the third largest U.S. market share holder in 2025 and projects $890 million in revenue for 2026, a 17% increase, with $130 million in Adjusted EBITDA and $20 million in free cash flow.
ATEC's strategy focuses on clinical distinction and proceduralization, driven by informatics tools like SafeOp, EOS, and the upcoming Valence navigation and robotic tool launching in 2026.
The company anticipates a new seasonality pattern, with stronger Q3s due to its growing presence in pediatric deformity, and views disruption from competitor spin-offs as advantageous.

6 days ago

Transcript

Alphatec (ATEC) Discusses Strong 2025 Performance and Provides 2026 Financial Guidance

ATEC

Guidance Update

Revenue Acceleration/Inflection

New Projects/Investments

Alphatec (ATEC) reported $764 million in revenue for 2025, reflecting 25% growth, with $91 million in adjusted EBITDA (12% of revenue) and positive cash flow.
For 2026, the company projects $890 million in revenue (17% growth), $130 million in adjusted EBITDA (15% margin), and $20 million in free cash flow.
Alphatec aims to achieve $1 billion in revenue, $180 million in adjusted EBITDA (18% margin), and $65 million in free cash flow by 2027.
The company's strategy emphasizes proceduralization, particularly in lateral surgery, and significant investment in informatics through systems like EOS Insight, SafeOp, and the Valence navigation and robotic tool, which is set to launch in 2026.
Alphatec became the third largest U.S. market share holder in 2025, with 2026 growth expected to be driven by $118 million in surgical growth and $8 million in EOS growth, targeting $100 million in EOS revenue by 2027.

6 days ago

Transcript

Alphatec Holdings and Theradaptive Announce Strategic Partnership for Spinal Fusion Technology

ATEC

New Projects/Investments

Alphatec Holdings (ATEC) has secured exclusive U.S. commercial rights to market and distribute Theradaptive's OsteoAdapt® osteoinductive bone graft for spinal fusion through a definitive strategic partnership. The agreement includes upfront and milestone payments to Theradaptive, along with a perpetual royalty structure.
OsteoAdapt, utilizing AMP2™ protein technology, is currently in clinical trials, subject to FDA PMA approval, and has received three FDA Breakthrough Device Designations. This technology targets the $2+ billion biologics segment within the $10+ billion U.S. spine surgery market.
To support the completion of clinical studies and rapid scaling of its technology platform, Theradaptive has initiated a Series B investment round.

7 days ago

Press Release

Alphatec Holdings, Inc. Announces Preliminary 2025 Results and 2026 Outlook

ATEC

Earnings

Guidance Update

New Projects/Investments

Alphatec Holdings, Inc. announced preliminary unaudited financial results for the full year ended December 31, 2025, with total revenue growing 25% to approximately $764 million and re-affirming adjusted EBITDA guidance of $91 million.
The company provided a financial outlook for full-year 2026, anticipating total revenue of $890 million, reflecting approximately 17% growth compared to 2025, and adjusted EBITDA of $130 million, which is expected to contribute to $20 million in free cash flow.
ATEC also announced the acquisition of exclusive U.S. distribution rights for Theradaptive’s OsteoAdapt®, a next-generation rhBMP-2 biologic, which expands the company's procedural offerings.

7 days ago

8-K

Alphatec Holdings Announces Preliminary 2025 Results and Provides 2026 Outlook

ATEC

Earnings

Guidance Update

New Projects/Investments

Alphatec Holdings (ATEC) announced preliminary full-year 2025 total revenue of approximately $764 million, reflecting 25% growth, and re-affirmed its adjusted EBITDA guidance of $91 million.
The company provided a full-year 2026 total revenue outlook of $890 million, which represents approximately 17% growth over 2025, with adjusted EBITDA expected to be approximately $130 million and free cash flow of $20 million.
ATEC also acquired exclusive U.S. distribution rights for Theradaptive’s OsteoAdapt®, a next-generation rhBMP-2 biologic, which is expected to expand the company's procedural offerings.

7 days ago

Press Release

Alphatec Management Outlines Growth Drivers and Robotics Strategy

ATEC

Revenue Acceleration/Inflection

New Projects/Investments

Product Launch

Alphatec (ATEC) reported outstanding Q3 lateral performance and sees significant growth potential in the lateral spine market, aiming to convert traditional posterior approaches with integrated technologies like navigation and Valence robotics.
The company plans to continue its outsized growth rate by expanding its sales force, attracting new surgeons (currently growing at a net rate of 20%), and leveraging new technologies such as the Valence robotics system and the EOS informatics platform for improved surgical decision-making and expanded applications in deformity and cervical surgery.
Alphatec is focused on self-funding its growth by 2026, with a strategy to invest $0.75 in sets and inventory for every $1 of revenue growth, and expects profitability in 2025 to be critical for this goal.
The Valence robotics system is designed with a small footprint and lower cost of goods, allowing for a disruptive placement strategy that avoids long capital cycles and targets both ASCs and small community hospitals.

Dec 2, 2025, 9:00 PM

Transcript

Alphatec Discusses Growth Drivers, Market Opportunities, and Self-Funding Outlook

ATEC

Revenue Acceleration/Inflection

New Projects/Investments

Guidance Update

Alphatec identifies substantial growth opportunities in the lateral spine market, estimated at $1 billion, with an additional $2 billion from traditional posterior approaches that could transition to lateral.
The company is driving growth through technological integration, including Valence (navigation robotics) to reduce radiation and improve predictability, and the EOS informatics platform, which is expected to significantly influence results from 2026-2028.
Alphatec projects absolute dollar growth of just under $150 million year-over-year, supported by a 20% net growth rate in surgeons and a higher average selling price (ASP).
Strategic expansion includes growing its sales force and increasing geographic penetration, aiming to replicate its 20% market share in highly penetrated areas across other regions.
The company anticipates achieving self-funding status by exiting 2025 into 2026, with profitability generating sufficient EBITDA to fund future investments in sets, inventory, and new technologies like Valence without needing to raise additional capital.

Dec 2, 2025, 9:00 PM

Transcript

Alphatec Highlights Strong Lateral Performance and Future Growth Drivers

ATEC

Revenue Acceleration/Inflection

New Projects/Investments

Alphatec (ATEC) reported outstanding lateral performance in Q3, with management indicating significant market expansion potential from the current $1 billion to potentially $2 billion by converting traditional posterior approaches.
Key growth catalysts include the integration of Valence navigation robotics to enhance precision and reduce radiation, expansion into complex pathologies like deformity, and the evolving EOS informatics platform.
The company projects nearly $150 million in absolute year-over-year growth for the current guide and views the Street's $130 million growth estimate for next year as achievable with potential to exceed.
Alphatec aims for self-funded growth by 2026, with a strategy to invest $0.75 in sets and inventory for every $1 of revenue growth, including $120 million invested in 2024 and $40-$50 million planned for 2025.

Dec 2, 2025, 9:00 PM

Transcript

ATEC Reports Strong Q3 2025 Results and Raises Full-Year Guidance

ATEC

Earnings

Guidance Update

Revenue Acceleration/Inflection

ATEC reported Q3 2025 total revenue of $197 million, a 30% increase year-over-year, with surgical revenue growing 31% and EOS revenue up 29%.
Adjusted EBITDA reached $26 million, representing 13% of revenue and an 840 basis point improvement compared to the prior year period.
The company generated $5 million in positive free cash flow for Q3 2025, marking its second consecutive quarter of positive free cash flow and the first time achieving positive free cash flow on a trailing 12-month basis.
Full-year 2025 guidance was raised, with expected total revenue of $760 million (up $18 million) and adjusted EBITDA of $91 million (up $8 million), implying a 12% adjusted EBITDA margin.
ATEC remains confident in achieving its 2027 long-range plan targets of $1 billion in revenue, 18% adjusted EBITDA, and $65 million of free cash flow, with an LRP update expected in late 2026.

Oct 30, 2025, 8:30 PM

Transcript

Earnings Transcripts

Quarterly earnings call transcripts for Alphatec Holdings.

Q3 2025

Oct 30, 2025

→

Q2 2025

Jul 31, 2025

→

View All Transcripts

Ask Fintool AI Agent

Get instant answers from SEC filings, earnings calls & more

What did Patrick S. Miles say about margins?What are Alphatec Holdings's strategic priorities?How is Alphatec Holdings positioned vs competitors?How did Alphatec Holdings do last quarter?

Alphatec Holdings (ATEC)

Analyst Earnings Quarterly Reports

Q4 2024

Q3 2024

Q2 2024

Q1 2024

Executives

Patrick S. Miles

Ali Shorooghi

Craig E. Hunsaker

David P. Sponsel

J. Todd Koning

Joseph Walland

Scott Lish

Tyson Marshall

Board Members

David Demski

David R. Pelizzon

Karen K. McGinnis

Keith Valentine

Mortimer Berkowitz III

Quentin Blackford

Ward W. Woods

Analyst Coverage

David Saxon

Brooks O'Neil

Matthew Miksic

Caitlin Cronin

Eric Anderson

Jason Wittes

Joshua Jennings

Mathew Blackman

Michaela Smith

Vikramjeet Chopra

Xun Lee

Young Li

Andrew Ranieri

Ben Haynor

Kallum Titchmarsh

Matthew O'Brien

Matt Miksic

Phillip Dantoin

Samantha Munoz

Sean Lee

Vik Chopra

Latest news

Earnings Transcripts

Q3 2025

Q2 2025

Ask Fintool AI Agent